EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Approval is based on results from the phase 3 OASIS 4 clinical trial
Consolidated entity plans to strengthen specialty pharmaceutical offerings, expand manufacturing capacity, and accelerate global market penetration across emerging regions
The company said Wegovy hit its first one million prescriptions within 12 weeks of availability
The move signals a major expansion in access to next-generation weight-loss therapies
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
